These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 486226)

  • 1. Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidemic agent.
    Edelson J; Benziger DP; Arnold A; Beyler AL
    Atherosclerosis; 1979 Jul; 33(3):351-7. PubMed ID: 486226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
    Arnold A; McAuliff JP; Powers LG; Phillips DK; Beyler AL
    Atherosclerosis; 1979 Feb; 32(2):155-63. PubMed ID: 454514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.
    Lupp A; Karge E; Danz M; Deufel T; Oelschläger H; Klinger W
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):203-18. PubMed ID: 16250258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
    Petit D; Bonnefis MT; Rey C; Infante R
    Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative hypolipidaemic activity and hepatic effects of ciprofibrate enantiomers in the rat.
    Graham MJ; Winham MA; Harpur ES; Bonner FW; Gray TJ
    Biochem Pharmacol; 1994 Dec; 48(12):2163-71. PubMed ID: 7811297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.
    Desager JP; Horsmans Y; Vandenplas C; Harvengt C
    Atherosclerosis; 1996 Jul; 124 Suppl():S65-73. PubMed ID: 8831918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits.
    Ismail MF; Gad MZ; Hamdy MA
    Pharmacol Res; 1999 Feb; 39(2):157-66. PubMed ID: 10072708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
    Domingos H; Cunha RV; Paniago AM; Souza AS; Rodrigues RL; Domingos JA
    Arq Bras Cardiol; 2012 Nov; 99(5):997-1007. PubMed ID: 23108642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypolipidemic effect of Telfairia occidentalis (fluted pumpkin) in rats fed a cholesterol-rich diet.
    Adaramoye OA; Achem J; Akintayo OO; Fafunso MA
    J Med Food; 2007 Jun; 10(2):330-6. PubMed ID: 17651070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.